Clinico-pathological factors predicting pathological response in early triple-negative breast cancerClara Helal, Luc Cabel, Anne Vincent‐Salomon et al.|npj Breast Cancer|2025Cited by 24
Abstract P2-12-23: A phase 2 trial combining tiragolumab and atezolizumab with neoadjuvant or first line chemotherapy for triple negative breast cancer (SKYLINE)François‐Clément Bidard, Fatima Mechta-Grigoriou, Romain‐David Seban et al.|Clinical Cancer Research|2025Cited by 0